← Evidence map

ArticleNature medicine2023

Author Correction: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial.

Tien Dam et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

2 papers cite it

2023
2024
2025
this papertrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 36253611